SEC Form 4 · accession 0001209191-16-100263
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Wiezorek
Officer — SVP Clinical Development
Period of report
Nov 30, 2015
Accepted (ET)
Feb 18, 2016 · 8:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 16, 2016 | M | 9,000 | $6.89 | A | 22,742 | D | |
| Common StockF2 | Feb 16, 2016 | S | 7,612 | $44.00 | D | 15,130 | D | |
| Common StockF3 | Feb 16, 2016 | S | 1,388 | $44.47 | D | 13,742 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F4 | $6.89 | Nov 30, 2015 | A | 25,000 | A | Nov 30, 2015 | Jun 5, 2024 | Common Stock | 25,000 | 25,000 | D |
| Employee Stock Option (Right to Buy) | $6.89 | Feb 16, 2016 | M | 9,000 | D | Nov 30, 2015 | Jun 5, 2024 | Common Stock | 9,000 | 16,000 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.37 to $44.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4On June 6, 2014, the reporting person was granted an option to purchase 25,000 shares of common stock, with vesting based exclusively on the Issuer's satisfaction of certain performance criteria. On November 30, 2015, the performance criteria was met, resulting in the full vesting of the option.